Menu
Minicircle is running Phase II clinical trials on a follistatin gene therapy that may be able to treat or delay the onset of age-related and autoimmunity-related muscle wasting disease.
Minicircle is also developing therapies to enhance testosterone levels, protect the brain from degeneration, and enhance skin quality.
TRIALS NOW RECRUITING
Currently in: Phase II
Trial recruitment active now
Follistatin in animal models has been shown to reduce chronic inflammation throughout all body tissues and in humans may be able to therapeutically target and regulate rheumatoid arthritis autoinflammation.
Currently in: Phase II
Trial recruitment active now
We believe follistatin gene therapy could be beneficial for treating FSHD for these simple reasons:
1. Follistatin gene therapy has been shown in FDA Phase II clinical trial results to be safe and effective at improving muscle size and walking distance over 180 days in patients with more severe forms of muscular dystrophy than FSHD.
2. Follistatin decreases chronic inflammation in all body tissues (Collins, 2017), improves neuromuscular junction innervation and function (Iyer, 2021), and improves muscle size, endurance, and power in rodent models of FSHMD (Giesige, C et al. 2018) as well as in healthy human clinical trials.
3. FSHD patients exhibit higher levels of myostatin activation than most other muscle wasting diseases, so follistatin is likely to be more effective against it. (Mariot, 2017).
Currently in: Phase I/II
Trial begins 2024
Follistatin has been shown in an FDA Phase I trial to improve outcomes for inclusion body myositis patients. IBM patients exhibit higher circulating levels of myostatin and activin than other muscle wasting diseases. Early results have indicated that follistatin may have excellent results at treating autoinflammatory diseases.
Currently in: Phase I
Trial begins 2024
Klotho is a hormone named after the Greek goddess of fate who would decide when a human would be born and when they would die. Klotho controls calcium and phosphate deposition sensitivity, circulating vitamin D levels, and extends lifespan in mice by 30%. Mice that were genetically modified to produce more klotho lived 30% longer and had greater cognitive function earlier and later in life. Humans that produce more klotho have an average of a 6 point higher IQ. Klotho may function as a neuroprotectant against age-related brain degeneration, as well as protect against vascular aging and age-related loss of kidney function.
Currently in: Phase II
Trial recruitment active now
We believe follistatin gene therapy could be beneficial for treating ALS for these simple reasons:
1. Follistatin gene therapy has been shown in FDA Phase II clinical trial results to be safe and effective at improving muscle size and walking distance over 180 days in muscular dystrophy patients.
2. Follistatin decreases chronic inflammation in all body tissues (Collins, 2017), improves neuromuscular junction innervation and function (Iyer, 2021), and improves muscle size, endurance, and power in rodent models of ALS (Holzbaur, 2006) as well as in humans. These three attributes address the unique manifold pathology of ALS.
3. Low follistatin levels are a key biomarker of ALS — only three proteins are reduced in ALS patients’ cerebral spinal fluid: follistatin-315, interleukin-1 alpha, and kallikrein-5. (Lind, A L et al, 2016).
Currently in: Phase I/II
Trial begins 2024
Testosterone is a master regulator hormone controlling self-confidence, risk-taking behavior, emotional stability, body composition, rational thinking, cognitive well-being, and libido. Low testosterone levels are endemic in modern civilization where sedentary lifestyles are common and industrial hyperestrogenic compounds are constantly consumed in our air, water, and food. To be considered for entrance into this trial you must have a circulating testosterone level of lower than 700 ng/dL.
Currently in: Phase I/II
Trial recruitment not active
Broadly neutralizing antibodies that bind to HSV 1 & 2 can be constantly produced and secreted into the bloodstream in hopes of minimizing or eliminating the transmission and symptoms of HSV.
Signing up early allows us to prioritize development of this program.
Currently in: Phase I/II
Trial recruitment not active
Our innovative therapy for Crohn’s disease uses plasmids to deliver TNF-alpha neutralizing antibodies at a constant rate for 1-2 years. This therapy, if successful should be able to replace the functionality of existing biologics.
Signing up early allows us to prioritize development of this program.